BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38452311)

  • 1. B-Cell-Mediated Immunity Predicts Survival of Patients With Estrogen Receptor-Positive Breast Cancer.
    Lee S; Kang BH; Lee HB; Jang BS; Han W; Kim IA
    JCO Precis Oncol; 2024 Mar; 8():e2300263. PubMed ID: 38452311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis.
    Lu C; Yang Y; Lingmei L; Qiujuan H; Qianru G; Lisha Q; Wenfeng C; Yun N; Peisen Z
    Breast Cancer Res Treat; 2023 Jan; 197(1):71-82. PubMed ID: 36334189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
    Wu JR; Zhao Y; Zhou XP; Qin X
    Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
    Wang Z; Liu H; Gong Y; Cheng Y
    Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
    Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
    BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
    Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Immune and Stroma Related Prognostic Marker for Invasive Breast Cancer in Tumor Microenvironment: A TCGA Based Study.
    Huang Y; Chen L; Tang Z; Min Y; Yu W; Yang G; Zhang L
    Front Endocrinol (Lausanne); 2021; 12():774244. PubMed ID: 34867821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.
    El-Ansari R; Craze ML; Alfarsi L; Soria D; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 May; 175(1):27-38. PubMed ID: 30671766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
    Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
    J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
    Ju J; Du F; Gao SL; Si YR; Hu NL; Liu DX; Wang X; Yue J; Zheng FC; Kang YK; Yang ZX; Ma F; Xu BH; Yuan P
    Breast Cancer Res Treat; 2022 Jul; 194(2):221-230. PubMed ID: 35699854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexpression of PBX1 and EMP2 as Prognostic Biomarkers in Estrogen Receptor-Negative Breast Cancer via Data Mining.
    Qiu Y; Lu G; Wu Y
    J Comput Biol; 2020 Oct; 27(10):1509-1518. PubMed ID: 32216630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors.
    Rangel N; Rondon-Lagos M; Annaratone L; Aristizábal-Pachon AF; Cassoni P; Sapino A; Castellano I
    Cells; 2020 Apr; 9(4):. PubMed ID: 32344660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
    El Ansari R; Alfarsi L; Craze ML; Masisi BK; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2020 May; 181(1):1-12. PubMed ID: 32200487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of immune environment in luminal B early breast cancer.
    Chan A; Gill J; Chih H; Nelson DJ
    Cancer Med; 2023 Apr; 12(7):8278-8288. PubMed ID: 36751105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer.
    Bonneau C; Eliès A; Kieffer Y; Bourachot B; Ladoire S; Pelon F; Hequet D; Guinebretière JM; Blanchet C; Vincent-Salomon A; Rouzier R; Mechta-Grigoriou F
    Breast Cancer Res; 2020 Jul; 22(1):76. PubMed ID: 32665033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
    Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
    Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of androgen receptor expression on clinical characterization of metastatic breast cancer.
    Kim JY; Park K; Lee E; Jung HH; Ahn JS; Im YH; Park WY; Park YH
    Oncotarget; 2017 Jan; 8(5):8693-8706. PubMed ID: 28060723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease.
    Zerdes I; Sifakis EG; Matikas A; Chrétien S; Tobin NP; Hartman J; Rassidakis GZ; Bergh J; Foukakis T
    Mol Oncol; 2020 May; 14(5):951-963. PubMed ID: 32115850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.